Platelet-type Bleeding Disorder 16 (BDPLT16): Comprehensive Disease Characteristics Report

Disease: Platelet-type Bleeding Disorder 16 (BDPLT16) Also known as: ITGA2B/ITGB3-related macrothrombocytopenia; Glanzmann thrombasthenia-like syndrome (GTLS); autosomal dominant macrothrombocytopenia with αIIbβ3 gain-of-function OMIM: #187800 · MONDO: MONDO:0008552 · ICD-10: D69.1 · Category: Mendelian (autosomal dominant)

Summary

Platelet-type Bleeding Disorder 16 (BDPLT16) is a rare, autosomal dominant inherited platelet disorder defined at the molecular level by heterozygous gain-of-function variants in ITGA2B (encoding integrin αIIb/GPIIb) or ITGB3 (encoding integrin β3/GPIIIa). These variants cluster in the membrane-proximal (transmembrane and cytoplasmic) region of the αIIbβ3 integrin and disrupt the conserved intracytoplasmic salt bridge between αIIb-Arg995 and β3-Asp723. Loss of this clasp releases the integrin from its resting conformation, producing a constitutively active αIIbβ3 receptor. This is the mechanistic inverse of classic Glanzmann thrombasthenia (GT), which is caused by recessive loss-of-function of the same genes.

Constitutive αIIbβ3 activation drives permanent "outside-in" signaling in megakaryocytes, which perturbs cytoskeletal (actin/tubulin) dynamics and produces abnormal proplatelet formation. The clinical consequence is a macrothrombocytopenia — large platelets present in reduced numbers — together with reduced αIIbβ3 surface expression (from receptor internalization), a partial (not absent) platelet aggregation defect, and lifelong, usually mild-to-moderate mucocutaneous bleeding (easy bruising, epistaxis, gum bleeding, menorrhagia). Enlarged and fused α-granules are seen ultrastructurally. Because the count is low and the platelets are large, patients are frequently misdiagnosed as immune thrombocytopenia (ITP) and treated ineffectively with corticosteroids/splenectomy.

BDPLT16 is genetically and mechanistically distinct from recessive GT; diagnosis rests on recognizing dominant inheritance, macrothrombocytopenia with reduced (not absent) αIIbβ3, a partial aggregation defect, and an activating membrane-proximal ITGA2B/ITGB3 variant on next-generation sequencing. No disease-specific or curative therapy exists; management is supportive and extrapolated from inherited platelet function disorders — antifibrinolytics (tranexamic acid), recombinant activated factor VII (rFVIIa), platelet transfusion for major bleeds/surgery, and hormonal control of heavy menstrual bleeding. This report synthesizes the molecular pathogenesis, phenotype, genetics, diagnostics, prognosis, treatment, and model systems across all requested disease-characteristic domains.

1. Disease Information

Overview. BDPLT16 is a Mendelian inherited platelet disorder in which a dominant gain-of-function lesion in the fibrinogen receptor αIIbβ3 produces large, poorly functional platelets in reduced numbers, causing a lifelong mild-to-moderate bleeding tendency. It belongs to the broader family of congenital macrothrombocytopenias and is a recognized subset now termed ITGA2B/ITGB3-related macrothrombocytopenia (PMID: 41503871).

Key identifiers.

Synonyms / alternative names. ITGA2B/ITGB3-related macrothrombocytopenia; Glanzmann thrombasthenia-like syndrome (GTLS); autosomal dominant macrothrombocytopenia with αIIbβ3 gain-of-function; αIIbβ3-related macrothrombocytopenia.

Source of information. Information is derived from aggregated disease-level resources (OMIM, MONDO) and from primary clinical/genetic case series and pedigrees of individual patients — not from population EHR datasets. The evidence base is a set of small multi-generational families reported worldwide (see Section 9).

2. Etiology

Primary cause — genetic (monogenic, dominant, gain-of-function). BDPLT16 is caused by heterozygous gain-of-function variants in ITGA2B or ITGB3. These are point mutations (and small in-frame deletions) concentrated in the membrane-proximal region of the integrin that destabilize the αIIb-R995/β3-D723 intracytoplasmic salt bridge, causing constitutive activation (PMID: 29090484; PMID: 29380037; PMID: 33276370).

Genetic risk factors. The causal variants are themselves the disease determinant; there are no known separate susceptibility loci. Documented disease alleles include (non-exhaustive): - ITGB3 (β3): p.Asp723His (D723H), p.Thr720del (T720del), D749H, T746P, H748P, R760C, plus membrane-proximal missense/deletion variants (e.g., C560R, βTD_del p.647-686 in Glanzmann-like macrothrombocytopenia). - ITGA2B (αIIb): p.Arg995Trp (R995W), R995Q, R1026W, R1026Q, G1007V.

Environmental / demographic risk factors. As a monogenic dominant disorder, the disease is not caused by environmental exposures. Relevant non-genetic modifiers of bleeding severity (not disease causation) are standard hemostatic challenges: surgery, trauma, dental extraction, childbirth/postpartum, menstruation, and antiplatelet/anticoagulant drug use. Female sex confers additional gynecologic/obstetric bleeding burden (menorrhagia, postpartum hemorrhage). A positive family history is a hallmark given dominant transmission.

Protective factors. No specific genetic or environmental protective factors are established. General avoidance of antiplatelet agents (aspirin, NSAIDs) reduces bleeding risk. There is no evidence of a protective allele.

Gene–environment interactions. No formal GxE interaction has been characterized. Practically, the penetrant genetic lesion sets a fixed platelet phenotype whose clinical expression is unmasked by hemostatic stressors (surgery, trauma, menstruation, delivery).

3. Phenotypes

BDPLT16 phenotypes comprise laboratory abnormalities and clinical bleeding signs/symptoms. Bleeding is typically mild-to-moderate, lifelong, and mucocutaneous; severity is variable even within families.

Age of onset. Congenital laboratory phenotype (thrombocytopenia/large platelets present from birth); bleeding symptoms emerge in childhood and persist lifelong. Severity is mild-to-moderate and variable; progression is stable (non-progressive), with bleeding episodic and provoked by hemostatic challenge.

Frequency among affected individuals. In the largest series (10 Portuguese GTLS families, 33 patients), the core lab tetrad — macrothrombocytopenia, low αIIbβ3 expression, impaired aggregation/ATP release, and low PAC-1 binding — was essentially universal, while clinical bleeding ranged from absent to moderate (PMID: 33276370).

Quality of life impact. Generally modest given mild-moderate severity, but recurrent epistaxis and especially menorrhagia can meaningfully impair quality of life and cause iron-deficiency anemia; peri-operative and peri-partum periods carry the highest morbidity risk. No disease-specific EQ-5D/SF-36 data are available.

4. Genetic / Molecular Information

Causal genes. ITGA2B (αIIb; HGNC:6138; OMIM 607759; 17q21.31) and ITGB3 (β3; HGNC:6156; OMIM 173470; 17q21.32). The two chains form the heterodimeric platelet fibrinogen receptor αIIbβ3 (GPIIb/IIIa, integrin αIIbβ3), expressed at ~60,000–80,000 copies per platelet in mouse and abundantly in human platelets (PMID: 11154120).

Pathogenic variants (representative).

Variant classification. ClinVar corroborates BDPLT16 alleles: ITGB3 Asp723His and ITGA2B Arg995 (R995W/R995Q) records are present, and ~8 ITGA2B records are annotated to "macrothrombocytopenia" (Finding F008). The majority of ITGA2B (≈345) and ITGB3 (≈266) pathogenic ClinVar entries reflect the allelic recessive Glanzmann thrombasthenia, not the rare dominant BDPLT16.

Variant type/class. Predominantly missense; also small in-frame deletions (T720del, βTD_del). All cluster in the membrane-proximal transmembrane/cytoplasmic interface.

Allele frequency. Disease alleles are private/ultra-rare and effectively absent from gnomAD, consistent with a highly penetrant dominant deleterious effect (Finding F008).

Somatic vs germline. Germline, heterozygous, dominantly inherited.

Functional consequence. Gain-of-function (constitutive integrin activation) — mechanistically opposite to the loss-of-function of classic GT. In-silico modeling shows mutated residues "directly modify the salt bridge linking the intra-cytoplasmic part of αIIb to β3" (PMID: 29090484).

Modifier genes / epigenetics / chromosomal abnormalities. No specific modifier genes, epigenetic marks, or large-scale chromosomal abnormalities are established for BDPLT16. The lesion is a point mutation / small in-frame deletion, not a copy-number or structural variant.

5. Environmental Information

BDPLT16 is a monogenic disorder with no environmental, lifestyle, or infectious etiology. No toxins, radiation, occupational exposures, dietary factors, or pathogens cause or trigger the disease. Environmental factors are relevant only as bleeding precipitants (trauma, surgery, dental procedures, childbirth) and as aggravators via antiplatelet/anticoagulant drug exposure (aspirin, NSAIDs). Not applicable: infectious agents.

6. Mechanism / Pathophysiology

Ordered causal chain

1. A heterozygous gain-of-function variant arises in ITGA2B (αIIb) or ITGB3 (β3) in the membrane-proximal region → disrupts the conserved αIIb-Arg995 ↔ β3-Asp723 intracytoplasmic salt bridge (the "clasp" that holds the integrin in its resting/bent state). (Demonstrated by in-silico + functional studies.)
2. Loss of the salt-bridge clasp releases the cytoplasmic/transmembrane restraint → the integrin adopts an extended, constitutively active conformation → spontaneous (agonist-independent) αIIbβ3 activation with increased binding of activation-specific ligands (↑PAC-1 binding; adhesion to fibrinogen/VWF under shear). (Demonstrated in CHO/293T transfectants and patient platelets.)
3. Constitutive ligand binding triggers permanent "outside-in" signaling → arrest of actin turnover at the polymerization stage and disordered cytoskeletal (actin/tubulin) reorganization in megakaryocytes. (Demonstrated.)
4. Cytoskeletal perturbation impairs proplatelet formation → megakaryocytes generate abnormal cytoplasmic extensions / asymmetric "barbell" proplatelets with fewer, larger tips. (Demonstrated in patient CD34+ MK cultures and cell models.)
5. Abnormal proplatelet fragmentation leads to incorrect platelet sizing and reduced platelet output → macrothrombocytopenia (large platelets, low count). (Demonstrated.)
6. Branch — receptor internalization: constitutive activation promotes αIIbβ3 internalization → reduced surface expression of the receptor on circulating platelets. (Demonstrated.)
7. Branch — granule abnormality: disordered biogenesis yields enlarged/fused α-granules (some giant). (Observed.)
8. Reduced receptor density + dysfunctional granule release + abnormal cytoskeleton → partial platelet aggregation and secretion defect (reduced but not absent responses to ADP, collagen, TRAP-6) → mild-to-moderate mucocutaneous bleeding when hemostasis is challenged. (Demonstrated clinically.)

GOF variant (ITGA2B/ITGB3, membrane-proximal)
│
▼
Disrupts αIIb-R995 / β3-D723 salt bridge (the "clasp")
│
▼
Constitutive αIIbβ3 activation (↑PAC-1, ligand binding)
├───────────────► Receptor internalization ─► ↓ surface αIIbβ3
│
▼
Permanent outside-in signaling ─► actin turnover arrested
│
▼
Abnormal proplatelet formation (asymmetric, few large tips)
│                         └──► enlarged/fused α-granules
▼
Large platelets + low count = MACROTHROMBOCYTOPENIA
│
▼
Partial aggregation/secretion defect ─► mild-moderate mucocutaneous bleeding

Detail by category

• Molecular pathways / biochemical abnormality. The defect is integrin bidirectional (inside-out/outside-in) signaling. The proximate biochemical lesion is loss of the electrostatic salt bridge that maintains the low-affinity resting state; the downstream signaling engages Rap1/talin-associated outside-in activation cascades and actin dynamics (PMID: 29380037; PMID: 26452979).
• Protein dysfunction. Gain-of-function conformational change: the mutant integrin is trapped in an active/extended state rather than misfolded or degraded. This distinguishes it from GT loss-of-function (absent/nonfunctional receptor).
• Cellular processes. Dysregulated cytoskeletal reorganization (actin polymerization/turnover, tubulin-dependent protrusions), abnormal proplatelet formation, and receptor endocytosis/internalization.
• Cell types involved. Megakaryocytes (CL:0000556) as the site of defective platelet production; platelets/thrombocytes (CL:0000233) as the dysfunctional end product.
• Suggested GO terms. GO:0007229 integrin-mediated signaling pathway; GO:0033628 regulation of cell adhesion mediated by integrin; GO:0030168 platelet activation; GO:0030220 platelet formation; GO:0007010 cytoskeleton organization; GO:0006897 endocytosis. Cellular component: GO:0009986 cell surface, GO:0031093 platelet alpha granule, GO:0015629 actin cytoskeleton.
• Immune / metabolic / infectious involvement. None intrinsic. (Misdiagnosis as immune thrombocytopenia is a clinical, not mechanistic, issue.)

Instructive natural experiment (sitosterolemia). In a murine sitosterolemia model, plant-sterol accumulation in the platelet membrane produced constitutive fibrinogen binding to αIIbβ3, receptor internalization, and macrothrombocytopenia — phenocopying, via a non-genetic route, the same "constitutively active αIIbβ3 → macrothrombocytopenia" logic and reinforcing causality (PMID: 23926302).

7. Anatomical Structures Affected

• Organ/system level. Primary involvement is the hematopoietic system / blood (UBERON:0000178 blood) and bone marrow (UBERON:0002371) where megakaryopoiesis occurs. The mucocutaneous vasculature (skin, nasal mucosa, gingiva, gastrointestinal and genitourinary mucosa) is the site of bleeding manifestations. Secondary involvement: endometrium/uterus (menorrhagia) and potential iron-deficiency anemia affecting systemic function.
• Tissue/cell level. Megakaryocytes (CL:0000556) in bone marrow; platelets/thrombocytes (CL:0000233) in circulation. No solid-organ parenchymal tissue is primarily targeted.
• Subcellular level. Plasma membrane / cell surface (integrin localization; GO:0005886), platelet α-granules (GO:0031093; enlarged/fused), and the actin cytoskeleton (GO:0015629).
• Localization / lateralization. Systemic (blood-borne); bleeding sites are not lateralized — diffuse mucocutaneous. No focal or asymmetric anatomic lesion.

8. Temporal Development

• Onset. Congenital laboratory phenotype (thrombocytopenia and large platelets from birth); clinical bleeding typically recognized in childhood. Onset pattern is chronic/insidious rather than acute.
• Progression. Stable / non-progressive; the platelet count and morphology remain relatively constant over life. Bleeding is episodic, provoked by hemostatic challenges (surgery, trauma, menstruation, delivery).
• Disease course / duration. Chronic, lifelong. There is no staging system and no natural tendency to remission or worsening.
• Critical periods. Windows of heightened vulnerability are surgical/dental procedures, trauma, menarche/menstruation, pregnancy and the peripartum period — the key opportunities for prophylactic hemostatic intervention.

9. Inheritance and Population

• Inheritance pattern. Autosomal dominant (heterozygous gain-of-function). Contrast with recessive classic GT.
• Epidemiology. No formal prevalence/incidence figures exist; BDPLT16 is ultra-rare, reported as a handful of families worldwide. Known pedigrees include the original ITGB3 D723H family (5 affected over 3 generations; PMID: 18065693), Japanese T720del and related families (PMID: 29380037), French salt-bridge families (PMID: 29090484), and a Portuguese cohort of 10 families/33 patients (PMID: 33276370).
• Penetrance / expressivity. Cosegregation is strong (the laboratory phenotype tracks with the variant across generations), implying high penetrance for the lab phenotype; bleeding severity is variably expressed (absent-to-moderate) even among carriers of the same allele.
• Anticipation / mosaicism / consanguinity / founder effects. No genetic anticipation (not a repeat-expansion disorder). No consanguinity required (dominant). The Portuguese cluster of 10 families may reflect ascertainment and/or shared alleles, but no formal founder haplotype has been established. Germline mosaicism not specifically documented.
• Carrier frequency. Not applicable in the recessive sense; disease alleles are private/ultra-rare and essentially absent from gnomAD (Finding F008).
• Population demographics. No strong ethnic predilection; cases reported across European (French, Portuguese, Italian) and Asian (Japanese) populations. Sex ratio for the genetic trait is ~1:1 (autosomal); affected women carry additional gynecologic/obstetric bleeding burden. Age distribution spans all ages given lifelong congenital nature.

10. Diagnostics

Laboratory tests. - CBC with peripheral blood smear: thrombocytopenia with large/giant platelets; increased mean platelet volume and platelet anisotropy. Automated counters may undercount large platelets. - Flow cytometry: reduced (not absent) αIIbβ3/GPIIb-IIIa surface expression; reduced PAC-1 binding upon stimulation (TRAP-6, ADP) — reflecting low activation-inducible binding sites. - Light transmission aggregometry (LTA): reduced but not absent aggregation to ADP and collagen; normal ristocetin-induced agglutination (distinguishing from Bernard-Soulier/VWD); reduced ATP/dense-granule release. - Electron microscopy (specialized): enlarged, sometimes fused α-granules; abnormal platelet morphology.

Biomarkers. The defining "biomarker" is the combination of macrothrombocytopenia + reduced (not absent) αIIbβ3 + partial aggregation defect + activating membrane-proximal ITGA2B/ITGB3 variant.

Genetic testing (definitive). - Recommended approach: NGS-based inherited platelet disorder gene panels covering ITGA2B, ITGB3, and the broader macrothrombocytopenia genes; WES/WGS are useful when panels are non-diagnostic. Confirm candidate variants by Sanger sequencing and test family segregation. - Single-gene testing of ITGA2B/ITGB3 is appropriate when phenotype is strongly suggestive. - CMA/karyotype/FISH/mtDNA/repeat-expansion testing are not applicable (point-mutation disorder).

Imaging / electrophysiology / biopsy. Not diagnostic; imaging is used only to evaluate bleeding complications. Bone marrow examination is typically normal (normal megakaryocyte numbers), useful mainly to exclude other causes.

Clinical criteria & differential diagnosis. No formal consensus criteria; diagnosis is integrative (phenotype + genetics). Differential diagnosis of dominant macrothrombocytopenia with platelet dysfunction includes:

Congenital macrothrombocytopenias "share common clinical and laboratory features... and patients are often misdiagnosed with and treated for idiopathic thrombocytopenic purpura" (PMID: 16169642).

Screening. No population/newborn screening. Cascade genetic testing of at-risk relatives is appropriate once a familial variant is identified; prenatal/preimplantation testing is technically feasible but rarely indicated given the mild phenotype.

11. Outcome / Prognosis

• Survival / life expectancy. Normal life expectancy; BDPLT16 is not associated with increased mortality in the absence of catastrophic bleeding. No disease-specific mortality data.
• Morbidity. Driven by bleeding: recurrent epistaxis, easy bruising, menorrhagia (with risk of iron-deficiency anemia), and peri-operative/peri-partum hemorrhage. Serious spontaneous bleeding (e.g., intracranial) is rare in mild-moderate disease, though documented in the severe allelic condition GT.
• Disease course. Chronic and stable; complications are episodic and largely preventable with appropriate hemostatic management around challenges.
• Prognostic factors. Bleeding phenotype severity, sex (gynecologic burden), exposure to antiplatelet drugs, and the nature of hemostatic challenges. No validated molecular prognostic biomarker; there is a broad genotype–phenotype trend (all activating salt-bridge variants → macrothrombocytopenia), but bleeding severity is variably expressed.
• Quality-of-life measures. No disease-specific EQ-5D/SF-36/PROMIS data; QoL is generally good but reduced in those with significant menorrhagia.

12. Treatment

Overarching principle. There is no BDPLT16-specific or curative therapy. Management is supportive/on-demand, extrapolated from inherited platelet function disorders and the allelic condition Glanzmann thrombasthenia.

Pharmacotherapy and hemostatic agents.

Evidence: in GT, "bleeding control was achieved through the use of antifibrinolytic agents and recombinant factor VIIa, which also reduces the risk of platelet alloimmunization" (PMID: 41778036). In women, "management of chronic HMB required a combination therapy including antifibrinolytics (tranexamic acid [TXA]), hormonal therapies, and recombinant factor VIIa (rFVIIa)" (PMID: 40123272). Local measures, desmopressin, and antifibrinolytics are first-line for mild inherited platelet disorders (PMID: 23269640).

Advanced / experimental therapeutics. No approved gene therapy, cell therapy, RNA-based, targeted, or immunotherapy for BDPLT16. Caution with anticoagulation — provoked thrombosis can occur in αIIbβ3 disorders and carries a narrow therapeutic window (PMID: 41591555, reported in GT).

Pharmacogenomics. Avoid antiplatelet drugs (aspirin, NSAIDs, P2Y12 inhibitors). No BDPLT16-specific pharmacogenomic guidance.

Treatment strategy. Individualized, challenge-based prophylaxis: pre-procedural antifibrinolytics ± rFVIIa ± platelets; peri-partum planning in a hemophilia/bleeding-disorder center; proactive management of menorrhagia and iron status.

13. Prevention

• Primary prevention. Not possible (genetic). Preventing bleeding events: avoid antiplatelet/anticoagulant drugs, use careful surgical/dental planning with prophylactic hemostatic cover.
• Secondary prevention. Early diagnosis (correctly distinguishing from ITP to avoid unnecessary steroids/splenectomy), cascade genetic testing of relatives, and iron-deficiency screening in menorrhagic patients.
• Tertiary prevention. Prevent complications: peri-operative/peri-partum hemostatic protocols, minimize platelet transfusions to reduce alloimmunization (favor rFVIIa where possible), treat anemia.
• Genetic counseling. Autosomal dominant → 50% transmission risk to offspring; counsel on variable bleeding expressivity; offer family-cascade testing; prenatal/PGT feasible but seldom pursued given mild phenotype.
• Immunization / public health / environmental interventions. Not applicable beyond general bleeding-risk counseling.

14. Other Species / Natural Disease

• Taxonomy / orthologs. Mouse orthologs Itga2b (NCBI Gene 16399) and Itgb3 (NCBI Gene 16416). Murine αIIbβ3 is functionally homologous to human, expressed at ~60,000–80,000 copies/platelet, with conserved EDTA-dissociation and activation biology (PMID: 11154120).
• Natural disease in other species. No well-characterized naturally occurring, dominant gain-of-function αIIbβ3 macrothrombocytopenia has been catalogued in companion animals for BDPLT16 specifically; naturally occurring Glanzmann thrombasthenia (loss-of-function) is documented in dogs and horses (OMIA), which is the allelic recessive disease rather than BDPLT16.
• Comparative biology. The αIIb-R995/β3-D723 salt bridge and integrin activation machinery are evolutionarily conserved, so the mechanistic principle (salt-bridge disruption → constitutive activation) is expected to be conserved across mammals.
• Zoonotic potential. None (non-transmissible genetic disorder).

15. Model Organisms

In vitro / cellular models (primary evidence base for BDPLT16). - Transfected cell lines (CHO, HEK293/293T) expressing mutant αIIbβ3 (β3-D723H/H723, β3-βTD_del p.647-686, β3-C560R, β3-T720del) reproduce constitutive activation, increased PAC-1 binding, adhesion to fibrinogen/VWF under shear, and formation of abnormal proplatelet-like cytoplasmic extensions not seen with wild-type (PMID: 18065693; PMID: 25806962; PMID: 29380037; PMID: 26452979). - Patient-derived CD34+ stem-cell megakaryocyte cultures confirm abnormal proplatelet formation in the propositus, directly linking the variant to the production defect (PMID: 18065693).

Mouse models. - The β3-integrin knockout (Itgb3⁻/⁻) mouse models loss-of-function Glanzmann thrombasthenia, NOT gain-of-function BDPLT16: "The mice are viable and fertile, and show all the cardinal features of GT (defects in platelet aggregation and clot retraction, prolonged bleeding times, and cutaneous and gastrointestinal bleeding)," plus placental defects and reduced survival (PMID: 9916135). - Sitosterolemia mouse (Abcg5/Abcg8⁻/⁻) provides a phenocopy of the mechanism — sterol-induced constitutive αIIbβ3 activation, internalization, and macrothrombocytopenia — even though the genetic cause differs (PMID: 23926302).

Phenotype recapitulation & limitations. No published knock-in mouse carrying a human BDPLT16 activating salt-bridge variant is established; thus the dominant gain-of-function macrothrombocytopenia is best modeled in vitro and in patient megakaryocytes, while mouse knockouts capture only the allelic loss-of-function disease. A conditional/knock-in Itgb3 D723H (or Itga2b R995W) mouse is an obvious gap.

Mechanistic Model / Interpretation

BDPLT16 is best understood as a "stuck-on" integrin disorder. The αIIbβ3 fibrinogen receptor normally rests in a bent, low-affinity conformation held by an intracellular clasp — the αIIb-R995 ↔ β3-D723 salt bridge. BDPLT16 variants break this clasp, so the receptor is constitutively active even without agonist. Paradoxically, this gain-of-function produces bleeding, because (a) chronic activation triggers receptor internalization, lowering surface density; and (b) permanent outside-in signaling freezes the megakaryocyte cytoskeleton, garbling proplatelet formation so platelets emerge too large and too few with impaired secretion. The result is a macrothrombocytopenia with a partial functional defect — the mirror image of Glanzmann thrombasthenia, where the same receptor is simply absent/nonfunctional and platelet number/size are normal.

This unifying logic explains every observed feature: dominant inheritance (a single active allele poisons proplatelet formation), reduced-not-absent αIIbβ3 (internalization vs. deletion), partial-not-absent aggregation, large fused α-granules, and mild-to-moderate bleeding. The sitosterolemia phenocopy independently validates the causal step "constitutive αIIbβ3 activation → internalization → macrothrombocytopenia."

BDPLT16 vs. classic Glanzmann thrombasthenia (allelic contrast).

Evidence Base

Verbatim supporting quotes. - "In silico analysis shows how the two mutated amino acids directly modify the salt bridge linking the intra-cytoplasmic part of αIIb to β3 of the integrin αIIbβ3." — PMID: 29090484 - "Reported mutations were highly clustered at the membrane proximal region of αIIbβ3, which affected the critical interaction between αIIb R995 and β3 D723, resulting in a constitutionally active form of the αIIbβ3 complex." — PMID: 29380037 - "the constitutive activation of the alphaIIbbeta3-H723 receptor causes abnormal proplatelet formation, leading to incorrect sizing of platelets and the thrombocytopenia observed in the pedigree." — PMID: 18065693 - "permanent triggering of αIIbβ3-mediated outside-in signaling causes an impairment of cytoskeletal reorganization arresting actin turnover at the stage of polymerization." — PMID: 26452979 - "Patients had absent to moderate bleeding, macrothrombocytopenia, low αIIbβ3 expression, impaired platelet aggregation/ATP release to physiological agonists and low expression of activation-induced binding sites on αIIbβ3 (PAC-1)." — PMID: 33276370 - "Many of these disorders share common clinical and laboratory features, making accurate diagnosis difficult and patients are often misdiagnosed with and treated for idiopathic thrombocytopenic purpura." — PMID: 16169642 - "Bleeding control was achieved through the use of antifibrinolytic agents and recombinant factor VIIa, which also reduces the risk of platelet alloimmunization." — PMID: 41778036

Limitations and Knowledge Gaps

1. No formal epidemiology. Prevalence/incidence are unknown; evidence is a handful of families. Penetrance and expressivity estimates are qualitative.
2. No in vivo gain-of-function model. No knock-in mouse (e.g., Itgb3 D723H or Itga2b R995W) has been established; mechanism relies on in vitro transfectants and patient megakaryocytes. Mouse Itgb3⁻/⁻ models only the allelic loss-of-function GT.
3. Mechanistic exceptions. Recent reports of non-activating ITGB3 variants causing macrothrombocytopenia challenge the uniform gain-of-function model (PMID: 41503871), indicating additional/alternative mechanisms remain to be defined.
4. Treatment evidence is extrapolated, not BDPLT16-specific — drawn from GT and general inherited platelet disorders; no trials in BDPLT16.
5. No QoL, natural-history, or prognostic-biomarker data specific to BDPLT16.
6. Genotype–phenotype correlation for bleeding severity is weak; modifier genes are unidentified.

Proposed Follow-up Experiments / Actions

1. Generate a knock-in mouse (Itgb3 p.D723H or Itga2b p.R995W) or iPSC-derived megakaryocyte lines to model dominant gain-of-function BDPLT16 in vivo and quantify proplatelet defects.
2. Systematic genotype–phenotype registry across reported families to estimate penetrance, expressivity, and bleeding-severity predictors.
3. Mechanistic dissection of non-activating ITGB3 macrothrombocytopenia variants to determine whether a distinct (activation-independent) pathway contributes.
4. Single-cell transcriptomics/proteomics of patient megakaryocytes to map the cytoskeletal and granule-biogenesis programs perturbed by constitutive αIIbβ3 signaling (GO:0030220 platelet formation).
5. Prospective evaluation of hemostatic strategies (antifibrinolytics ± rFVIIa vs. platelet transfusion) to build BDPLT16-specific, alloimmunization-sparing protocols.
6. ClinVar/ACMG reclassification effort to curate BDPLT16 alleles distinctly from recessive GT alleles, improving diagnostic reporting.

Report compiled from 8 confirmed findings and 28 reviewed papers across 5 investigation iterations. Evidence types: human clinical pedigrees/case series, in vitro heterologous-cell and patient-megakaryocyte studies, and mouse models. Ontology suggestions (HPO, GO, CL, UBERON, NCIT) are provided throughout for knowledge-base population.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:40123272 (abstract only): "management of chronic HMB required a combination therapy including antifibrinolytics (tranexamic acid [TXA]), hormonal therapies, and recombinant factor VIIa (rFVIIa)"
• closest text in source: "management of chronic HMB required a combination therapy including antifibrinolytics (tranexamic acid [TXA]), hormonal therapies, and recombinant factor VIIa (rFVIIa)"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0008552 (2 mentions) - the report calls it "MONDO"; MONDO calls it platelet-type bleeding disorder 16

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• CL:0000233 (2 mentions) - the report calls it "platelets/thrombocytes"; CL calls it platelet, and lists "anucleate thrombocyte" among its other names